Focal segmental glomerulosclerosis treatment

Dl. Dall Amico, R., Ghiggeri, G., Carraro, M., Artero, M., Ohio, L., Zamorani, E., Zennaro, C., Basile, G., Montini, G., Rivabella, L., Cardillo, M., Scalamogna, M., and Ginevri, F., Prediction and treatment of recurrent focal segmental glomerulosclerosis after renal transplantation in children. Am. J. Kidney Dis. 34, 1048-1055 (1999). 

Ingulli, E., and Tejani, A., Incidence, treatment and outcome of recurrent focal segmental glomerulosclerosis posttransplantation in 42 allografts in children A single-center experience. Transplantation 51, 401—405 (1991). 

K25. Kriz, W., Hahnel, B., Rosener, S., and Eiger, M., Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int. 48, 1435-1450 (1995). 

Schreiner A, Waldherr R, Rohmeiss P, Hewer W. Focal segmental glomerulosclerosis and lithium treatment. Am J Psychiatry 2000 157(5) 834. 

Markowitz, GS, Appel, GB, Fine, PL. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamid-ronate. J Am Soc Nephrol, 12 1164-72, 2001. 

Nephrotoxicity of bisphosphonates is a known complication of this compound class, often exacerbated by diseases that compromise renal function, such as multiple myeloma, and by concomitant use of antineo-plastic agents, steroids, and radiation therapy. The first reports of tubulointerstitial damage after treatment with etidronate and clodronate appeared more than 2 decades ago [60]. Subsequently, acute tubular necrosis, focal segmental glomerulosclerosis (FSGS), and granulomatous interstitial nephritis have been reported in renal biopsies from predominantly cancer patients exposed to several bisphosphonates, often at high i.v. doses. 

Usta M, Ersoy A, Dilek K, et al. Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. J Intern Med 2003 253 329-334. 

Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002 62 2301-2310. 

Ponticelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis Am J Kidney Dis 1999 34 618-625. 

Chishti AS, Sorof JM, Brewer ED, et al. Long-term treatment of focal segmental glomerulosclerosis in children with cyclosporine given as a single daily dose. Am J Kidney Dis 2001 38 754—760. 

Matalon A, Valeri A, Appel GB. Treatment of focal segmental glomerulosclerosis. Sem Nephrol 2000 20 309-317. 

Ittel TFI, Clasen W, Fuhs M, Kindler J, Mihatsch MJ, Sieberth FIG. Long-term dclosporine A treatment in adults with minimal change nephrotic syndrome or focal segmental glomerulosclerosis. Clin Nephrol 1995 44 156-162. 

Torres, V.E., Velosa, J.A., Holley, K.E., Frohnert, P.P., Zincke, H. and Sterioff, S. (1984). Meclofenamate treatment of recurrent idiopathic nephrotic syndrome with focal segmental glomerulosclerosis after renal transplantation. Mayo Clin. Proc., 59, 149—52... 

Duncan N, Dhaygude A, Owen J, CairnsTD, Griffith M, McLean AG, Palmer A,Taube D.Treatment of focal and segmental glomerulosclerosis in adults with tracrolimus monotherapy. Nephrol Dial Transplant 2004 19 3062-3067. 

---